MEXICOWANDERER
las peñas, michoacan, mexico
Senior Member
Joined: 06/01/2007
View Profile
 Offline
|
This is exactly why I posted specifics with regard to vaccine efficacy versus physical effects. What I left unsaid was vaccine efficacy with regard to downstream lab tests.
If a subject tests asymptomatic positive with zero communicability and acceptable inherent immune response, is this a true positive checkmark?
Acceptable universal medical definitions need to be established and adhered to.
My idea of a goal is to eliminate individual corporate variances in the meaning of the word "is"
This is why I celebrated the fact of learning that no FDA approved has permitted a properly vaccinated individual of any age from being infected to the point where they needed acute medical attention. Indeed, the incidence of the vaccinated being troubled by future COVID-19 symptoms has never been reported to the news media.
I, too, am looking forward to the British head-to head trials of various vaccines. Last year's troubled history of the AstraZeneca serum is a role model for standardization of trials.
IMHO the world medical community has performed a miracle developing high efficacy safe vaccines. But glaring questions remain.
Why the wild variance between Oxford University and AZ corporate over dosage and efficacy over their vaccine. The seeming astonishing high final efficacy of the Pfizer and Moderna serums in single dose format is another eye-opener. Extremely welcome in my opinion. The month's long halting of AZ trials in the USA while Europe paused for a week is another of my questions. The FDA has never released one word publically why the resumption took so long. Coupled with the University versus corporate arguments, the lengthy USA delay is quite curious.
I won't be here to see it play out, but the world has entered a new phase of intercommunicable animal human viral transmission.
Standardizing laboratory human trials definitions is a must, and it is needed sooner than later.
I wish to append a hearty DAMNED WELL DONE to all medical and drug personnel who have contributed to mitigating a worldwide disaster.
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
Quote:If a subject tests asymptomatic positive with zero communicability and acceptable inherent immune response, is this a true positive checkmark?
Asymptomatic cases are communicable; this is the major difference between Covid-19 and other respiratory viral diseases (like Flu, MERS, etc).
In the Phase 3 trials symptoms trigger testing. I think the AstraZeneca trial is the only one where testing occurred regardless of symptoms but under the clinical trail design, asymptomatic RT-PCR positive cases will not count as a Covid case for the determination of effectiveness.
|
MEXICOWANDERER
las peñas, michoacan, mexico
Senior Member
Joined: 06/01/2007
View Profile
Offline
|
Excellent presentation of just how complicated and difficult serum component sourcing is...
Johns Hopkins Link
https://blogs.sciencemag.org/pipeline/ar........02/22/more-on-mrna-vaccine-manufacturing
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
Here is another study assessing if patients with previous infections or ones that have been vaccinated have antibodies that can neutralize the South African variant.
(one of my employer's products was used to measure how effective the antibodies are at binding to the RBD of several variants)
Quote:Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
bioRxiv preprint doi: https://doi.org/10.1101/2021.02.20.432046
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19
individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.
* This post was
edited 02/23/21 08:58am by BCSnob *
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
Get ready to hear more reports about the Southern California variant (B.1.429) which may be responsible for the surge in cases in CA at the end of 2020.
Emergence of a Novel SARS-CoV-2 Variant in Southern California
|
|
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
J&J one shot vaccine is being reviewed by the FDA for EUA.
FDA Briefing Document
Janssen (Johnson & Johnson) Ad26.COV2.S Vaccine for the Prevention of COVID-19
The data indicates it is not as effective as Moderna’s or Pfizer’s vaccines; however, the mix of variants present during the phase 3 clinical trials of those vaccines was different than the current mix of variants.
* This post was
edited 02/24/21 07:50am by BCSnob *
|
dturm
Lake County, IN
Moderator
Joined: 01/29/2001
View Profile
Good Sam RV Club Member
Offline
|
BCSnob wrote:
The data indicates it is not as effective as Moderna’s or Pfizer’s vaccines; however, the mix of variants present during the phase 3 clinical trials of those vaccines was different than the current mix of variants.
I heard that explanation too. The recommendation is to get which ever vaccine is available at your location at the earliest available time. Don't try to pick and choose which one you will get.
Doug & Sandy
Kaylee (16-year-old Terrier of some sort)
Winnie 4 1/2 year old golden
Sasha and many others at the Rainbow Bridge
2008 Southwind
2009 Honda CRV
Check out blog.rv.net
|
MEXICOWANDERER
las peñas, michoacan, mexico
Senior Member
Joined: 06/01/2007
View Profile
Offline
|
Reminds me of snubbing one brand of extinguisher for another during a fire.
|
MEXICOWANDERER
las peñas, michoacan, mexico
Senior Member
Joined: 06/01/2007
View Profile
Offline
|
Here we go again.
Hews media announcement of a "unique" California mutation
No reference to South African or British variant. No sense of perspective for viral loading, infectivity, intensity. Nothing
what a load of balderdash.
They're contriving hysteria to sell their product.
All mutations affect disease characteristics
But unless Johns Hopkins denotes an increase in hazard I ignore such drivel but I tend to hold it against that media source.
I also tell myself universal masking requirements after immunization will help to expose anti-maskers who would risk the not yet immunized segment of the population.
There has been far too many cases of damage to children to calculate risk and immunity factors for adults alone.
Like Churchill famously said during World War Two
"It is the end of the beginning"
|
JaxDad
Greater Toronto Area
Senior Member
Joined: 08/02/2011
View Profile
Good Sam RV Club Member
Offline
|
MEXICOWANDERER wrote:Reminds me of snubbing one brand of extinguisher for another during a fire.
The difference as I see it though is the fire extinguisher is the first of several layers of assault on the fire, culminating with the strong young men in the shiny red truck.
When it comes to vaccines the one you get will likely be the ONLY one you get.
It’s one of those things in life where you really want to get it right the first time.
|
|
|
